Keith D. Dawkins - Concepedia

Author

Keith D. Dawkins

Also Known As

K Dawkins, K. D. Dawkins, KEITH D. DAWKINS, KEITH DAWKINS, Keith D Dawkins, Keith D. Dawkins, Keith DAWKINS, Keith Dawkins

276

Publications

25.7K

Citations

H-Index

Concepts

All Affiliations

Boston Scientific (United States)Erasmus MC Erasmus University Rotterdam Deutsches Herzzentrum der Charité Hôpital Privé Jacques Cartier

About

Keith D. Dawkins is an author at Boston Scientific (United States) specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	58	10K
2	Public Health	19	21	4.6K
3	Health Sciences	4	4	469
4	Engineering	1	1	50
5	Nursing	1	1	54

Keith D. Dawkins

131

Publications

24.5K

Citations

H-Index

Page 1

	Year	Citations
Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease Patrick W. Serruys, Marie‐Claude Morice, A. Pieter Kappetein, New England Journal of Medicine	2009	4.3K
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. Georgios Sianos, Marie‐Angèle Morel, Arie Pieter Kappetein, PubMed Cardiac AnaesthesiaAngiographic ToolSouthampton General HospitalCoronary Artery DiseasePublic Health	2005	2.3K
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial Friedrich W. Mohr, Marie-Claude Morice, A. Pieter Kappetein, The Lancet Cardiac SurgeryPercutaneous Coronary InterventionEndovascular TechniqueCardiovascular DiseaseClinical Syntax Trial	2013	1.8K
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents Gregg W. Stone, Jeffrey W. Moses, Stephen G. Ellis, New England Journal of Medicine	2007	1.6K
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II Vasim Farooq, David van Klaveren, Ewout W. Steyerberg, The Lancet Cardiac SurgeryPercutaneous Coronary InterventionCardiovascular DiseaseClinical Decision-makingMedicine	2013	813
Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial Marie-Claude Morice, Patrick W. Serruys, A. Pieter Kappetein, Circulation	2010	640
Assessment of the SYNTAX score in the Syntax study Patrick Serruys, Yoshinobu Onuma, Scot Garg, EuroIntervention	2009	635
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial Daniel J.F.M. Thuijs, A. Pieter Kappetein, Patrick W. Serruys, The Lancet Percutaneous Coronary InterventionControlled Syntax TrialEndovascular TechniqueCardiovascular DiseaseHealth Policy	2019	618
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial A. Pieter Kappetein, Ted Feldman, Michael J. Mack, European Heart Journal	2011	562
Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial Marie-Claude Morice, Patrick W. Serruys, A. Pieter Kappetein, Circulation	2014	526

Page 1